{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:44:52Z","timestamp":1792025092907,"version":"4.4.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI158666"],"award-info":[{"award-number":["R01AI158666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI078881"],"award-info":[{"award-number":["R01AI078881"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying individuals with hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antivirals (DAA) therapy would support the effort to reach HCV elimination goals. To date, clinical studies of short-duration DAA therapy based on early (eg, days 2 or 7) HCV RNA levels (eg, &amp;lt; 500 IU\/mL) have used arbitrary time points and viral load thresholds, and yielded suboptimal cure rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A database of HCV-host parameters was built based on mathematically modeling time to cure in about 300 individuals with recent (duration &amp;lt; 12 months) or chronic infection treated with DAAs. Two hundred thousand parameter combinations of viral-host and treatment parameters were generated, each representing an in silico HCV patient under DAA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We assessed response-guided treatment (RGT) strategies based on whether HCV RNA was undetectable on day 7 or day 14 on treatment. The analysis predicted that treatment duration could be shortened to 5 or 7 weeks for people with recent or chronic infection who have undetectable HCV RNA at day 7 or day 14 of treatment, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Modeling suggested that most people with recent or chronic HCV treated with DAAs will have undetectable HCV RNA by day 7 or 14 and could have their treatment duration reduced to 5 or 7 weeks. This modeling-independent RGT approach could improve treatment access, facilitate HCV elimination, and reduce cost, particularly in key populations most affected by HCV, such as people who inject drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag260","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:37:57Z","timestamp":1778153877000},"page":"547-555","source":"Crossref","is-referenced-by-count":3,"title":["Modeling Predicts Direct-Acting Antiviral Therapy for 5-Weeks May Cure Recent or Chronic Hepatitis C Infection Among People With Undetectable Viral RNA by Day 7"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-3379","authenticated-orcid":false,"given":"Ashish","family":"Goyal","sequence":"first","affiliation":[{"name":"The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Cotler","sequence":"additional","affiliation":[{"name":"The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-6396","authenticated-orcid":false,"given":"Gail V","family":"Matthews","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-1673","authenticated-orcid":false,"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Biostatistics, and Preventive Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center , Albuquerque, New Mexico ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6663-6253","authenticated-orcid":false,"given":"Tatyana","family":"Kushner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Weill Cornell Medicine , NewYork, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Etzion","sequence":"additional","affiliation":[{"name":"Soroka University Medical Center Department of Gastroenterology and Liver Diseases, , Beersheva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"Marianne","family":"Martinello","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-1817","authenticated-orcid":false,"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[{"name":"The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"2026101419582663100_jiag260-B1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101419582663100_jiag260-B2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: conquering mount improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin Liver Dis"},{"key":"2026101419582663100_jiag260-B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","article-title":"Hepatitis C virus elimination: laying the foundation for achieving 2030 targets","volume":"18","author":"Dore","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026101419582663100_jiag260-B4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2055-6640(20)30264-8","article-title":"Report from the international viral hepatitis elimination meeting (IVHEM), 17-18 November 2017, Amsterdam, The Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework","volume":"4","author":"Popping","year":"2018","journal-title":"J Virus Erad"},{"key":"2026101419582663100_jiag260-B5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S2468-1253(23)00408-9","article-title":"WHO hepatitis C elimination targets: the global equity challenge","volume":"9","author":"Heath","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026101419582663100_jiag260-B6","author":"Center for Disease Analysis"},{"key":"2026101419582663100_jiag260-B7","author":"World Health Organization"},{"key":"2026101419582663100_jiag260-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026101419582663100_jiag260-B9","doi-asserted-by":"crossref","first-page":"e81801","DOI":"10.7554\/eLife.81801","article-title":"Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study","volume":"12","author":"Flower","year":"2023","journal-title":"Elife"},{"key":"2026101419582663100_jiag260-B10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(25)00097-2","article-title":"Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial","volume":"405","author":"Cooke","year":"2025","journal-title":"Lancet"},{"key":"2026101419582663100_jiag260-B11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study","volume":"1","author":"Lau","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026101419582663100_jiag260-B12","doi-asserted-by":"crossref","first-page":"ofac157","DOI":"10.1093\/ofid\/ofac157","article-title":"Modeling-based response-guided DAA therapy for chronic hepatitis C to identify individuals for shortening treatment duration","volume":"9","author":"Goyal","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582663100_jiag260-B13","doi-asserted-by":"crossref","first-page":"108756","DOI":"10.1016\/j.mbs.2021.108756","article-title":"Machine learning for mathematical models of HCV kinetics during antiviral therapy","volume":"343","author":"Churkin","year":"2022","journal-title":"Math Biosci"},{"key":"2026101419582663100_jiag260-B14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21037\/atm-21-1297","article-title":"Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis","volume":"9","author":"Xia","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026101419582663100_jiag260-B15","first-page":"113","article-title":"Real-life experience of hepatitis C treatment with direct-acting antivirals in genotypes 2 and 3","volume":"37","author":"Kaya","year":"2025","journal-title":"Turk J Gastroenterol"},{"key":"2026101419582663100_jiag260-B16","doi-asserted-by":"crossref","first-page":"ofx264","DOI":"10.1093\/ofid\/ofx264","article-title":"Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection","volume":"5","author":"Collins","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582663100_jiag260-B17","doi-asserted-by":"crossref","first-page":"105899","DOI":"10.4254\/wjh.v17.i6.105899","article-title":"Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs","volume":"17","author":"Dobrowolska","year":"2025","journal-title":"World J Hepatol"},{"key":"2026101419582663100_jiag260-B18","doi-asserted-by":"crossref","first-page":"ofz100","DOI":"10.1093\/ofid\/ofz100","article-title":"Effectiveness of direct-acting antiviral therapy in patients with human immunodeficiency virus-hepatitis C virus coinfection in routine clinical care: a multicenter study","volume":"6","author":"Kim","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582663100_jiag260-B19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/jvh.13936","article-title":"Direct-acting antivirals in women of reproductive age infected with hepatitis C virus","volume":"31","author":"Dobrowolska","year":"2024","journal-title":"J Viral Hepat"},{"key":"2026101419582663100_jiag260-B20","doi-asserted-by":"crossref","first-page":"ofae704","DOI":"10.1093\/ofid\/ofae704","article-title":"Characteristics and outcomes of direct-acting antiviral experienced patients with hepatitis C undergoing retreatment at an essential hospital in the United States","volume":"11","author":"De La Hoz","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582663100_jiag260-B21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/tropicalmed8020092","article-title":"Genotypes of hepatitis C virus and efficacy of direct-acting antiviral drugs among chronic hepatitis C patients in a tertiary care hospital","volume":"8","author":"Hawsawi","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2026101419582663100_jiag260-B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello","year":"2020","journal-title":"Hepatology"},{"key":"2026101419582663100_jiag260-B23","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/j.jhepr.2023.100867","article-title":"Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: the TARGET3D study","volume":"5","author":"Martinello","year":"2023","journal-title":"JHEP Rep"},{"key":"2026101419582663100_jiag260-B24","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101419582663100_jiag260-B25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mbs.2013.04.012","article-title":"Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents","volume":"245","author":"Rong","year":"2013","journal-title":"Math Biosci"},{"key":"2026101419582663100_jiag260-B26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2017.06.019","article-title":"Modeling HCV cure after an ultra-short duration of therapy with direct acting agents","volume":"144","author":"Goyal","year":"2017","journal-title":"Antiviral Res"},{"key":"2026101419582663100_jiag260-B27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/liv.12692","article-title":"Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics","volume":"35","author":"Dahari","year":"2015","journal-title":"Liver Int"},{"key":"2026101419582663100_jiag260-B28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"2026101419582663100_jiag260-B29","doi-asserted-by":"crossref","first-page":"104862","DOI":"10.1016\/j.antiviral.2020.104862","article-title":"Modeling based response guided therapy in subjects with recent hepatitis C infection","volume":"180","author":"Gorstein","year":"2020","journal-title":"Antiviral Res"},{"key":"2026101419582663100_jiag260-B30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jiaa219","article-title":"Modeling-based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration","volume":"222","author":"Dasgupta","year":"2020","journal-title":"J Infect Dis"},{"key":"2026101419582663100_jiag260-B31","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci Rep"},{"key":"2026101419582663100_jiag260-B32","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","article-title":"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir","volume":"64","author":"Dahari","year":"2016","journal-title":"J Hepatol"},{"key":"2026101419582663100_jiag260-B33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/liv.14014","article-title":"Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis","volume":"39","author":"Gambato","year":"2019","journal-title":"Liver Int"},{"key":"2026101419582663100_jiag260-B34","doi-asserted-by":"crossref","first-page":"e0187409","DOI":"10.1371\/journal.pone.0187409","article-title":"HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients","volume":"12","author":"Canini","year":"2017","journal-title":"PLoS One"},{"key":"2026101419582663100_jiag260-B35","author":"AbbVie"},{"key":"2026101419582663100_jiag260-B36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2016.04.006","article-title":"Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens","volume":"65","author":"Maasoumy","year":"2016","journal-title":"J Hepatol"},{"key":"2026101419582663100_jiag260-B37","doi-asserted-by":"crossref","first-page":"e0229994","DOI":"10.1371\/journal.pone.0229994","article-title":"Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C","volume":"15","author":"Lin","year":"2020","journal-title":"PLoS One"},{"key":"2026101419582663100_jiag260-B38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jvh.13454","article-title":"High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting","volume":"28","author":"Fabbiani","year":"2021","journal-title":"J Viral Hepat"},{"key":"2026101419582663100_jiag260-B39","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1002\/jmv.26652","article-title":"Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir\/velpatasvir for chronic hepatitis C: an open-label study","volume":"93","author":"Chua","year":"2021","journal-title":"J Med Virol"},{"key":"2026101419582663100_jiag260-B40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/cid\/ciaf305","article-title":"Short course therapy with glecaprevir\/pibrentasvir for early hepatitis C virus infection: pURGE-C","volume":"81","author":"Kim","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026101419582663100_jiag260-B41","doi-asserted-by":"crossref","first-page":"S821","DOI":"10.1016\/S0168-8278(24)02261-X","article-title":"THU-389 sustained virological response after early discontinuation of HCV treatment","volume":"80","author":"Flisiak","year":"2024","journal-title":"J Hepatol"},{"key":"2026101419582663100_jiag260-B42","author":"AbbVie"},{"key":"2026101419582663100_jiag260-B43","doi-asserted-by":"crossref","first-page":"e240302","DOI":"10.1001\/jamahealthforum.2024.0302","article-title":"Changes in use of hepatitis C direct-acting antivirals after access restrictions were eased by state Medicaid programs","volume":"5","author":"Davey","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026101419582663100_jiag260-B44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/ciaf166","article-title":"Cost-effectiveness analysis of testing approaches for diagnosis of hepatitis C among US adults","volume":"81","author":"Hall","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026101419582663100_jiag260-B45","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s12325-023-02539-5","article-title":"Shorter duration hepatitis C virus treatment is associated with better persistence to prescription refills in people who inject drugs: a real-world study","volume":"40","author":"Martinez","year":"2023","journal-title":"Adv Ther"},{"key":"2026101419582663100_jiag260-B46","first-page":"S85","article-title":"Eight versus twelve weeks of sofosbuvir\/velpatasvir for treatment-naive non-cirrhotic chronic hepatitis C virus: an interim analysis of a multicentric, open label, randomized, non-inferiority (RESOLVE) trial","volume":"82","author":"Goel","year":"2025","journal-title":"Hepatology"},{"key":"2026101419582663100_jiag260-B47","doi-asserted-by":"crossref","first-page":"ofad027","DOI":"10.1093\/ofid\/ofad027","article-title":"Modeling-based response-guided hepatitis C treatment during pregnancy and postpartum","volume":"10","author":"Kushner","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582663100_jiag260-B48","author":"Food and Drug Administration"},{"key":"2026101419582663100_jiag260-B49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/infdis\/jiaf608","article-title":"Development of a rapid automated point-of-care test for hepatitis C viral RNA on the DASH rapid polymerase chain reaction system","volume":"233","author":"Reed","year":"2026","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag260\/68254283\/jiag260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/547\/68254283\/jiag260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/547\/68254283\/jiag260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:58:42Z","timestamp":1792022322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/4\/547\/8674198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,9]]},"published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag260","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,5,9]]}}}